제2형 당뇨병 환자에서 스타틴 치료 시 HDL 콜레스테롤의 변화
The effect of statins on HDL-cholesterol in type 2 diabetic patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims : Statins have been a mainstay of treatment for primary and secondary prevention of coronary heart disease through their beneficial effect on lipid profile. However, their effect on the HDL cholesterol level has been determined to be equivocal or unclear. This study sought to investigate HDL cholesterol response to statin treatment in type 2 diabetic patients. Methods : We retrospectively assessed the effect of statins in 217 patients with type 2 diabetes and dyslipidemia through chart review. Patients who were using medications such as fibrates, niacin, or thiazolidinediones, or had a plasma creatinine concentration greater than 1.5 mg/dL, a fasting triglyceride level greater than 300 mg/dL, or chronic liver disease, were excluded from the study. Result : The mean level of LDL cholesterol was significantly decreased, and the percentage of patients who achieved the normal LDL cholesterol level was increased in this study. The mean HDL cholesterol level after statin treatment was decreased by 2.3%. The percent change of HDL cholesterol was affected by baseline HDL cholesterol level, percent change of total cholesterol, percent change of LDL cholesterol, and baseline total cholesterol level. When subjects were divided into quintiles according to baseline HDL cholesterol, HDL cholesterol level was found to be increased in the lowest two quintiles while it was decreased in the highest two quintiles. Conclusions : There were some patients whose HDL cholesterol level was decreased after statin treatment, depending on their baseline HDL cholesterol level. We think further study on the effect of statins on HDL level will be needed in the future. (Korean J Med 74:411-417, 2008)
Abstract
Background/Aims : Statins have been a mainstay of treatment for primary and secondary prevention of coronary heart disease through their beneficial effect on lipid profile. However, their effect on the HDL cholesterol level has been determined to be equivocal or unclear. This study sought to investigate HDL cholesterol response to statin treatment in type 2 diabetic patients. Methods : We retrospectively assessed the effect of statins in 217 patients with type 2 diabetes and dyslipidemia through chart review. Patients who were using medications such as fibrates, niacin, or thiazolidinediones, or had a plasma creatinine concentration greater than 1.5 mg/dL, a fasting triglyceride level greater than 300 mg/dL, or chronic liver disease, were excluded from the study. Result : The mean level of LDL cholesterol was significantly decreased, and the percentage of patients who achieved the normal LDL cholesterol level was increased in this study. The mean HDL cholesterol level after statin treatment was decreased by 2.3%. The percent change of HDL cholesterol was affected by baseline HDL cholesterol level, percent change of total cholesterol, percent change of LDL cholesterol, and baseline total cholesterol level. When subjects were divided into quintiles according to baseline HDL cholesterol, HDL cholesterol level was found to be increased in the lowest two quintiles while it was decreased in the highest two quintiles. Conclusions : There were some patients whose HDL cholesterol level was decreased after statin treatment, depending on their baseline HDL cholesterol level. We think further study on the effect of statins on HDL level will be needed in the future. (Korean J Med 74:411-417, 2008)
참고문헌 (18)
- Scandanavian Simvastatin Survival Study, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease", Lancet, 344, pp.1383~1389 (1994)
- Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia", N Engl J Med, 333, pp.1301~1307 (1995)
- Sever PS, "Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes", Diabetes Care, 28, pp.1151~1157 (2005)
- Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- Gordon T, "High density lipoprotein as a protective factor against coronary heart disease", Am J Med, 62, pp.707~714 (1977)
- Gordon DJ, "High-density lipoprotein cholesterol and cardiovascular disease", Circulation, 79, pp.8~15 (1989)
- Bruckert E, "Low HDL- cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan- European survey", Diabet Med, 24, pp.388~391 (2007)
- Le Goff W, "Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia", Pharmacol Ther, 101, pp.17~38 (2004)
- Schaefer JR, "Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease", Atherosclerosis, 144, pp.177~184 (1999)
- Jones P, "Comparative dose efficacy study of atorvastatin versus simvastatin, prava-statin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)", Am J Cardiol, 81, pp.582~587 (1998)
- Streja L, "Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West of Scotland Coronary Prevention Study (WOSCOPS)", Am J Cardiol, 90, pp.731~736 (2002)
- Chapman MJ, "Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease", Pharmacol Ther, 111, pp.893~908 (2006)
- Kajinami K, "Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atrorvastatin: interaction with apolipoprotein AI gene polymorphism", Atherosclerosis, 178, pp.331~338 (2005)
- Mahaney MC, "A major locus influencing plasma high-density lipoprotein cholesterol levels in the San Antonio Family Heart Study: segregation and linkage analyses", Arterioscler Thromb Vasc Biol, 15, pp.1730~1739 (1995)
- Austin MA, "Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins", Am J Hum Genet, 62, pp.406~419 (1998)
- Knoblauch H, "Haplotypes and SNPs in 13 lipid- relevant genes explain most of the genetic variance in high- density lipoprotein and low-density lipoprotein cholesterol", Hum Mol Genet, 13, pp.993~1004 (2004)
- Lahoz C, "Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy", Atherosclerosis, 168, pp.289~295 (2003)